Independent Bank Corp (Massachusetts)

INDB · NASDAQ

$80.88+$1.42 (+1.79%)TodayMarket closed ·
Prev close $79.46

INDB analyst rating

HoldConsensus of 5 analysts over the last 12 months. 60% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold1
  • Underperform1
  • Sell0

12-month price target · 9 analysts

Average $94.57 (+16.9% upside)

Low
$82.82
Now
$80.88
High
$105.00

Upgrades and downgrades

The latest rating actions, newest first

INDB analyst upgrades, downgrades and rating actions
FirmDateActionRating
Keefe, Bruyette & WoodsJul 20, 2026MaintainsOutperform
Piper SandlerJun 26, 2026MaintainsNeutral
Hovde GroupMay 15, 2026InitiatesOutperform
Keefe, Bruyette & WoodsApr 20, 2026MaintainsOutperform
Stephens & Co.Apr 16, 2026InitiatesOverweight
BarclaysApr 7, 2026MaintainsUnderweight
Piper SandlerMar 16, 2026InitiatesNeutral
BarclaysFeb 2, 2026DowngradeEqual-Weight → Underweight
BarclaysDec 17, 2025InitiatesEqual-Weight
Keefe, Bruyette & WoodsOct 21, 2025UpgradeMarket Perform → Outperform

The case for and against

Updated Oct 7, 2026

Bull case

Independent Bank is well positioned because its high-quality New England deposit franchise, including 28% non-interest-bearing deposits and a 1.46% all-in deposit cost, supports a funding advantage that should widen margins as securities repricing and loan remixing work through the balance sheet. Management also pointed to improving operating momentum, with 4Q25 operating EPS of $1.70, NIM up 15bps sequentially, C&I growth of 6.8% annualized, and strong wealth management revenues, while credit metrics improved as NPAs/assets fell to 0.34% from a peak of 0.54%. In addition, the company has excess capital for continued share repurchases, potential 2026 ROA recovery toward 1.37% versus 1.13% in 2025, and a favorable longer-term earnings backdrop from better NIM, controlled expenses, and lower provisioning.

Bear case

Independent Bank is facing a weaker fundamental setup because estimates were cut for 2026E and 2027E due to balance-sheet timing shifts and modestly higher expenses, while the recent $0.09 miss reflected lower net interest income, higher costs, and a higher provision. Credit remains a central concern even though NPAs fell 3.4% to 0.34% of total assets, since “problem” assets are still 0.59% of total loans and the stock appears to carry lingering credit stigma. Its valuation is also pressured by elevated exposure to Boston CRE, including about $1.1B in office loans as of 4Q25 and a 289% CRE concentration near the 300% regulatory threshold, leaving limited room for error if regional or rate-related conditions soften.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.